SEC FORM 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0104
Expires:	December 31, 2014
Estimated average burden
hours per response:		0.5

1. Name and Address of Reporting Person ^*

Illumina Innovation Fund II GP, L.L.C.

(Last)

(First)

(Middle)

500 LINCOLN CENTRE DRIVE, SUITE 110

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/16/2026

3. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A-3 Preferred Stock	⁽¹⁾	⁽¹⁾	Class B Common Stock	1,321,082	⁽¹⁾	I	See Footnote ⁽²⁾
Series A-4 Preferred Stock	⁽¹⁾	⁽¹⁾	Class B Common Stock	1,183,832	⁽¹⁾	I	See Footnote ⁽²⁾
Series B Preferred Stock	⁽³⁾	⁽³⁾	Class B Common Stock	922,152	⁽³⁾	I	See Footnote ⁽²⁾
Series C Preferred Stock	⁽¹⁾	⁽¹⁾	Class B Common Stock	2,083,450	⁽¹⁾	I	See Footnote ⁽²⁾
Convertible Promissory Note	⁽⁴⁾	⁽⁴⁾	Common Stock	346,020	⁽⁴⁾	I	See Footnote ⁽²⁾
Convertible Promissory Note	⁽⁴⁾	⁽⁴⁾	Common Stock	271,782	⁽⁴⁾	I	See Footnote ⁽⁵⁾

Explanation of Responses:

1. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis, at the holder's election, and will automatically convert into shares of the Issuer's common stock upon the closing of the initial public offering pursuant to their terms. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock have no expiration date.

2. The securities are held by Illumina Innovation Fund II, L.P. ("IIF II"). Illumina Innovation Fund II GP, L.L.C. ("IIF II GP") is the general partner of IIF II. Nicholas Naclerio ("Mr. Naclerio"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any.

3. The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis, at the holder's election, and will automatically convert into shares of the Issuer's common stock upon the closing of the initial public offering pursuant to their terms. The Series B Preferred Stock has no expiration date.

4. Reflects a convertible note that is convertible into shares of common stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note together with any accrued but unpaid interest will be automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock multiplied by 0.85.

5. The securities are held by Illumina Innovation Fund III, L.P. ("IIF III"). Illumina Innovation Fund III GP, L.L.C. ("IIF III GP") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any.

	/s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund II GP, L.L.C.	04/16/2026
	** Signature of Reporting Person	Date
	/s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund II GP, L.L.C., the general partner of Illumina Innovation Fund II, L.P.	04/16/2026
	** Signature of Reporting Person	Date
	/s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund III GP, L.L.C.	04/16/2026
	** Signature of Reporting Person	Date
	/s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund III GP, L.L.C., the general partner of Illumina Innovation Fund III, L.P.	04/16/2026
	** Signature of Reporting Person	Date
	/s/ Nicholas Naclerio	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.